| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | UTHR United Therapeutics Corp | Sullivan Louis W62 | Director | Sell | 26,209 | $373.22 | $9,781,714.72 | -6.1% | -12.1% | +41.8% | |
| Dec 18, 2024 | SCLX Scilex Holding Co | Shah Jaisim | See Remarks | Buy | 30,000 | $0.46 | $13,800.00 | +27.4% | -32.7% | -9.1% | |
| Dec 17, 2024 | ESPR Esperion Therapeutics, Inc. | Halladay Benjamin | Chief Financial Officer | Sell | 3,245 | $2.42 | $7,865.88 | -1.3% | -37.4% | +48.4% | |
| Dec 17, 2024 | ESPR Esperion Therapeutics, Inc. | Warren Eric60 | Chief Commercial Officer | Sell | 2,234 | $2.43 | $5,426.39 | -1.4% | -37.4% | +48.4% | |
| Dec 17, 2024 | ESPR Esperion Therapeutics, Inc. | Koenig Sheldon L.63 | President And CEO | Sell | 12,447 | $2.47 | $30,694.30 | -1.7% | -37.4% | +48.4% | |
| Dec 17, 2024 | ANIP Ani Pharmaceuticals Inc | Carey Stephen P.55 | SVP &CFO | Sell | 7,500 | $55.79 | $418,425.00 | -4.6% | +15.3% | +47.5% | |
| Dec 17, 2024 | NBIX Neurocrine Biosciences Inc | Delaet Ingrid67 | Chief Regulatory Officer | Sell | 1,091 | $135.00 | $147,285.00 | -30.3% | -18.4% | +3.7% | |
| Dec 17, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 204,907 | $30.47 | $6,244,283.94 | -11.5% | +11.5% | +12.4% | |
| Dec 17, 2024 | HIMS Hims & Hers Health, Inc. | Chi Michael | Chief Commercial Officer | Sell | 25,550 | $32.20 | $822,710.00 | -11.7% | +11.5% | +12.4% | |
| Dec 17, 2024 | HIMS Hims & Hers Health, Inc. | Becklund Irene | Pao | Sell | 10,484 | $32.08 | $336,348.16 | -29.8% | +11.5% | +12.4% | |
| Dec 16, 2024 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 10,000 | $370.14 | $3,701,377.29 | -20.8% | -13.4% | +34.1% | |
| Dec 16, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 23,017 | $20.44 | $470,467.48 | -19.3% | +13.0% | +103.6% | |
| Dec 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | See Remarks | Sell | 165 | $0.35 | $58.13 | -0.8% | -64.9% | -71.1% | |
| Dec 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO And President | Sell | 3,117 | $0.36 | $1,131.27 | -2.5% | -64.9% | -71.1% | |
| Dec 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Sell | 577 | $0.36 | $206.98 | -1.4% | -64.9% | -71.1% | |
| Dec 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 430 | $0.36 | $153.02 | -0.9% | -64.9% | -71.1% | |
| Dec 16, 2024 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 430 | $0.35 | $151.82 | -0.7% | -64.9% | -71.1% | |
| Dec 16, 2024 | ORGO Organogenesis Holdings Inc. | Gillheeney Gary S.73 | President And CEO | Sell | 61,200 | $3.37 | $206,358.05 | -1.0% | +40.0% | +45.6% | |
| Dec 13, 2024 | AVDL Avadel Pharmaceuticals Plc | McHugh Thomas S73 | Chief Financial Officer | Buy | 2,300 | $10.44 | $24,018.67 | +2.7% | -19.2% | +105.6% | |
| Dec 13, 2024 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 250 | $56.24 | $14,060.00 | -0.4% | +8.6% | +42.1% | |
| Dec 13, 2024 | PCRX Pacira Biosciences, Inc. | Gaugler Daryl67 | Chief Operating Officer | Sell | 500 | $19.76 | $9,880.00 | -0.4% | +14.2% | +32.4% | |
| Dec 13, 2024 | BCRX Biocryst Pharmaceuticals Inc | Hutson Nancy J58 | Director | Sell | 7,000 | $7.54 | $52,780.00 | -7.5% | +0.1% | +0.5% | |
| Dec 13, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | Senior EVP, Production Center | Sell | 15,000 | $44.85 | $672,815.00 | -6.0% | -37.9% | -40.2% | |
| Dec 12, 2024 | JNJ Johnson & Johnson | Weinberger Mark A | Director | Buy | 1,000 | $147.22 | $147,220.00 | New | +11.4% | +44.7% | |
| Dec 12, 2024 | ETST Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | Buy | 100,000 | $0.12 | $12,000.00 | +8.0% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.